Skip to content

The Transcriptomic Study of Thai Patients With Atopic Dermatitis by Tape Strips

The Transcriptomic Study of Thai Patients With Atopic Dermatitis by Tape Strips

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05598762
Enrollment
100
Registered
2022-10-28
Start date
2022-12-31
Completion date
2024-07-31
Last updated
2022-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

tape strips, endotype

Brief summary

This study will be use the tape strip technique to evaluate the skin biomarkers of atopic dermatitis among Thai patients to differentiate clinical phenotype.

Detailed description

The patients will be enrolled in this study if they have been diagnosed with atopic dermatitis. All participants (AD patients and controls) will be evaluated their skin biomarkers by using tape stripping. The tape strips will be applied to the antecubital fossa to collect the epithelial samples. Then RNA was extracted from the tape strips for mRNA profiling to identify the immune and epidermal barrier genes.

Interventions

GENETICTape strips

Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

Sponsors

Mahidol University
CollaboratorOTHER
Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
Samitivej Hospital group
CollaboratorUNKNOWN
Queen Sirikit National Institute of Child Health
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Children (age 1-18 years old) with mild atopic dermatitis * Children (age 1-18 years old) with moderate to severe atopic dermatitis * Children (age 1-18 years old) with moderate to severe atopic dermatitis and food allergy * Adult (age 18-60 years old) with atopic dermatitis * Healthy individuals (1-60 years old) * Patients with asthma (1-60 years old)

Exclusion criteria

* Active skin infections * Used systemic immunosuppressants within 4 weeks * Used topical steroids or immunomodulators within 1 week * Used moisturizers within 12 hours before evaluation

Design outcomes

Primary

MeasureTime frameDescription
Cellular AD biomarkers1 monthEvaluated by RNA sequencing: RNA was extracted for real-time polymerase chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0
Immune biomarkers1 monthEvaluated by RNA sequencing: RNA was extracted for real-time polymerase chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0
Barrier biomarkers1 monthchain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0

Countries

Thailand

Contacts

Primary ContactPanipak Temboonnark, MD
panipak.ny@gmail.com+1929-823-2424
Backup ContactTassalapa Daengsuwan, MD
tassalapa@gmail.com+668-1822-1368

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026